Shares of biotech giant Celgene (CELG) may be worth $200 per share if peak sales of late-stage assets, including luspatercept, ozanimod, and GED301 are met, said analyst Ying Huang. LUSPATERCEPT: Lusp...
What’s the safest investment as the global economy enters increasingly risky, troubled times? I’ve reviewed hundreds of academic papers, investment reports and newsletters and researched ...
Former IMF chief economist Ken Rogoff warned today on CNBC that he was concerned about China. Specifically, he worried that country might “export a recession” to the rest of Asia if not the re...
No doubt, elements of the current market condition can make one uneasy. Like driving a hotrod going 100 mph without a seatbelt on, getting long up at these levels can feel death defying. Just look at ...
Tom Denham, the editor of Elliott Wave International’s Metals Pro Service, tells you about the importance of the market’s price momentum and explains what momentum is saying about the tre...
The Chart of the Day belongs to Pieris Pharmaceuticals (PIRS). I found the biopharmaceutical stock by using Barchart to sort today’s All Time High list first for the highest Weighted Alpha...
Brandon Macdonald, the CEO of Fireweed Zinc joined me to discuss the company’s large Zinc-Lead-Silver deposits known as Tom and Jason. Fireweed has an extremely tight share structure, experienced m...
There’s been a lot of talk about the so-called FAANG stocks and parallels being drawn against the 2000’s dot com bubble. With S&P500 valuations steadily pushing higher vs history and r...